Derms on Drugs takes on the AAD late breaking research, Part 1

Late-breaking clinical trial abstracts from the American Academy of Dermatology meeting reveal significant advancements and limitations in dermatological therapeutics. Roflumilast 0.05% cream demonstrates efficacy in infants with atopic dermatitis, while the STAT6 degrader KT-621 emerges as a promising, clean-profile alternative to JAK inhibitors. Conversely, OX40 ligand blockade for atopic dermatitis shows underwhelming efficacy and potential risks for Kaposi's sarcoma. Research into alopecia areata treatments, such as the IL-2 receptor antibody Respeg, highlights the challenge of balancing immune regulation with long-term safety. Additionally, TIK2 inhibition with inbutacitinib provides robust PASI 100 results for psoriasis, and anti-C5A therapy with vilobelumab offers a novel approach for pyoderma gangrenosum. These findings underscore the ongoing shift toward targeted, mechanism-specific interventions, though clinical adoption remains contingent on balancing efficacy, side effect profiles, and long-term durability.